Related references
Note: Only part of the references are listed.All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J. Iland et al.
BLOOD (2012)
The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia
Karen A. Breen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia
Harry Iland et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Oral administration of arsenic trioxide in the treatment of acute promyelocytic leukaemia and accelerated phase chronic myeloid leukaemia: an Australian single-centre study
F. Firkin
INTERNAL MEDICINE JOURNAL (2012)
Oral arsenic trioxide for relapsed acute promyelocytic leukemia in pediatric patients
Wing Y. Au et al.
PEDIATRIC BLOOD & CANCER (2012)
Oral arsenic trioxide-based maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study
Wing-Yan Au et al.
BLOOD (2011)
Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid
Jae H. Park et al.
BLOOD (2011)
Phase II Study of Single-Agent Arsenic Trioxide for the Front-Line Therapy of Acute Promyelocytic Leukemia
Ardeshir Ghavamzadeh et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome
Miguel A. Sanz et al.
BLOOD (2010)
BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia
Yukiya Yamamoto et al.
BLOOD (2010)
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
Francesco Lo-Coco et al.
BLOOD (2010)
Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710
Bayard L. Powell et al.
BLOOD (2010)
Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
Steven D. Gore et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data
Vikram Mathews et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: A systematic review
Amer Beitinjaneh et al.
LEUKEMIA RESEARCH (2010)
Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients
Chong-Wen Dai et al.
ACTA HAEMATOLOGICA (2009)
Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia
Wing-Yan Au et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Comparison of Clinical Outcomes of Patients with Relapsed Acute Promyelocytic Leukemia Induced with Arsenic Trioxide and Consolidated with Either an Autologous Stem Cell Transplant or an Arsenic Trioxide-Based Regimen
Rajasekar Thirugnanam et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Miguel A. Sanz et al.
BLOOD (2009)
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia
Jiong Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy
Wing-Yan Au et al.
BLOOD (2008)
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis
Syed Khizer Hasan et al.
BLOOD (2008)
Acute promyelocytic leukemia: from highly fatal to highly curable
Zhen-Yi Wang et al.
BLOOD (2008)
The seventh pathogenic fusion gene FIP1L1-RARA was isolated from a t(4;17)-positive acute promyelocytic leukemia
Takeshi Kondo et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines
Z. Diaz et al.
LEUKEMIA (2008)
Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation
Rihab Nasr et al.
NATURE MEDICINE (2008)
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
Alberto Catalano et al.
BLOOD (2007)
Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia
Ahmed Aribi et al.
CANCER (2007)
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARα-positive leukemic stem cells
Xiaomin Zheng et al.
HAEMATOLOGICA (2007)
Is cytarabine useful in the treatment of acute promyelocytic leukemia?: Results of a randomized trial from the European Acute Promyelocytic Leukemia Group
Lionel AdeS et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release
Haimei Chen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety
Chung-Wah Siu et al.
BLOOD (2006)
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
E Estey et al.
BLOOD (2006)
Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity
V Mathews et al.
BLOOD (2006)
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
A Ghavamzadeh et al.
ANNALS OF ONCOLOGY (2006)
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: Updated outcomes of the phase II study and postremission therapies
K Shigeno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
DNA topoisomerase II in therapy-related acute promyelocytic leukemia
AR Mistry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
All-trans retinoic acid/AS2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
ZX Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia
E Raffoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease
AR Mistry et al.
BLOOD REVIEWS (2003)
Use of arsenic trioxide (AS2O3) in the treatment of patients with acute promyelocytic leukemia -: The M. D.!Anderson experience
G Lazo et al.
CANCER (2003)
Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia
WY Au et al.
ANNALS OF ONCOLOGY (2003)
Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies
CR Kumana et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
G Avvisati et al.
BLOOD (2002)
PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model
LM Kelly et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report
DP Lu et al.
BLOOD (2002)
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
SL Soignet et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
PD Kottaridis et al.
BLOOD (2001)
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage
Y Shen et al.
LEUKEMIA (2001)
Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: Clinicopathological and molecular features of a pilot study
YL Kwong et al.
AMERICAN JOURNAL OF HEMATOLOGY (2001)
Share Paper
